Bethesda III/IV甲状腺细胞学样本中DICER1突变的多中心观察研究
该多中心回顾性研究分析了88例经ThyroSeq v3分子检测发现体细胞DICER1突变的Bethesda III/IV甲状腺结节患者,平均年龄39.6岁,女性为主。大多数切除结节组织学为良性(65.9%),但该队列恶性率高于全国平均水平。DICER1突变可能 confer 较高恶性风险,但无特异性细胞学或组织病理学特征。
要点
- Bethesda III/IV甲状腺结节中DICER1突变多见于体细胞热点区,尤其是密码子5437。
- 携带DICER1突变的结节多数组织学良性(65.9%),但恶性率高于全国平均。
- DICER1突变无特异性细胞学或组织病理学特征,诊断需结合分子检测。
核心结论
- DICER1突变可能增加甲状腺结节恶性风险,但无特异性细胞学或组织病理学特征。
研究设计与样本
- 多中心回顾性观察研究,纳入88例Bethesda III/IV甲状腺结节且细针穿刺细胞学样本经ThyroSeq v3检测发现体细胞DICER1突变的患者。
主要发现
- 所有突变位于体细胞热点区,最常见于密码子5437位点。
- 大多数切除结节组织学为良性(65.9%)。
- 该队列恶性率高于全国平均水平。
- 平均年龄39.6岁,女性 predominance。
临床怎么用
- 对Bethesda III/IV结节行ThyroSeq v3检测发现DICER1突变时,应警惕恶性风险,但不能仅凭突变做出诊断。
局限性
- 回顾性研究设计。
- 部分结节缺乏组织病理学结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mutations in DICER1 are uncommon, poorly understood, and infrequently found in thyroid nodules. METHODS: The objective of this study was to investigate category III/IV thyroid nodules according to The Bethesda System for Reporting Thyroid Cytopathology with DICER1 gene mutations detected in fine-needle aspiration cytology samples using ThyroSeq v3 molecular testing, with a focus on an exploration of the clinical and histopathologic outcomes of these nodules. In this multicenter study spanning more than 6 years, nodules were retrospectively analyzed for patient demographics, clinical course, cytologic features, and histopathology, where available. RESULTS: In total, 88 patients with somatic DICER1 mutations were included, with a mean age of 39.6 years and a female predominance. All mutations were in the somatic hotspot region, most commonly at the codon 5437 site. Most excised nodules showed benign histologic features (65.9%). Interestingly, the rate of malignancy was higher in this cohort compared with that in the national average. CONCLUSIONS: DICER1 mutations appear to confer a higher risk of malignancy, but are not associated with any specific cytological or histopathological distinguishing features.
引用
- Karimkhan A, Xia R, Diaz D, et al. DICER1 mutations in Bethesda III/IV thyroid cytology samples: A multicenter observational study. Cancer Cytopathol. 2025. PMID: 40937607. doi:10.1002/cncy.70045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。